Compass Pathways Resolves FDA Chemistry Concerns, Targets Q4 2026 NDA Submission
CMPS•Compass Pathways resolved the FDA’s chemistry, manufacturing and controls queries in a recent Type A meeting, boosting its regulatory positioning for its psilocybin-based therapy. The company plans to submit its New Drug Application by late 2026, aiming to address the $14 billion treatment-resistant depression market.
1. FDA Chemistry Clearance
Compass Pathways recently resolved the FDA’s chemistry, manufacturing and controls queries during a Type A meeting, removing a key obstacle ahead of its New Drug Application filing. This progress reinforces the company’s regulatory strategy for its psilocybin-based treatment for patients with treatment-resistant depression.
2. Upcoming NDA Submission and Market Outlook
With CMC questions addressed, Compass Pathways plans to submit its NDA by late 2026. The therapy aims to tap into a roughly $14 billion treatment-resistant depression market, positioning the company for potential commercialization by mid-2027.
